X4 Pharmaceuticals XFOR Cash Flow Statement (2017-2026)

NASDAQ XFOR
$2.99 -0.03 (-0.99%)
As of: Oct 21, 2026 · 3:12 PM EDT
Reported Financials

X4 Pharmaceuticals Quarterly Cash Flow Statement

Periods 38 quarters
Latest Jun 2026

X4 Pharmaceuticals reported cash from operations of -$20.80M and free cash flow of -$20.80M for the quarter ended Jun 2026, up 30.4% year over year. This cash flow statement covers 38 quarters of results from Mar 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-20.18M-30.21M-21.97M-21.21M-21.59M-29.10M-24.02M-55.71M-2.31M-19.13M-51.77M90.83M-36.70M-39.82M0.28M-25.74M-29.82M-23.90M-20.24M-16.16M
Depreciation and DepletionDep. & Depletion
0.10M0.04M0.06M0.07M0.08M0.09M0.29M0.17M0.04M0.04M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.13M0.13M0.13M0.13M0.12M0.12M0.13M0.13M0.10M0.06M0.06M0.19M0.27M0.27M0.48M0.36M0.22M0.22M0.22M1.00M
Share-based CompensationStock Comp.
1.52M1.61M1.46M1.52M1.11M1.11M1.65M2.14M2.36M2.54M1.74M2.43M1.82M2.22M0.52M0.75M0.76M2.27M2.41M3.09M
Gains from Sales and DivestituresGains Divest
Gains from Investment SecuritiesGains Investment
Other non-cash itemsOther Non-Cash
0.98M0.44M0.39M1.18M3.31M-4.88M30.47M-24.53M-5.86M14.28M-19.78M2.24M3.14M-10.37M-1.06M1.62M0.39M0.42M0.03M
Change in Working Capital
Change in ReceivablesChange Receivables
1.07M-0.56M0.64M-0.25M-0.32M0.54M0.93M
Change in InventoryChange Inventory
0.83M1.61M0.37M0.27M0.08M0.91M0.40M0.16M0.87M
Change in Account PayablesChange Payables
-0.10M1.86M-0.71M0.11M0.12M3.91M-1.71M-1.10M3.24M0.81M0.00M-0.95M0.58M0.08M2.48M-3.44M-2.65M0.64M-0.62M-1.14M
Change in Accured ExpensesChange Accured Exp.
1.92M-1.22M-0.98M1.64M0.65M2.50M0.50M4.53M0.63M-4.04M1.26M2.74M-0.17M3.34M-7.78M0.23M3.37M2.17M-1.55M-2.93M
Change in Other Operating AssetsOther Assets Change
-1.87M1.74M-1.63M0.81M0.66M0.77M-2.08M1.61M0.02M1.83M-1.06M-0.34M0.20M0.51M-0.20M-0.24M-0.42M-3.39M-0.78M3.02M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.19M-0.23M-0.24M-0.24M-0.25M-0.16M-0.25M-0.28M-0.31M-0.29M-0.24M-0.25M-0.26M-0.26M1.54M-0.52M-1.08M-0.59M-0.32M0.14M
Other Working Capital ChangesOther WC Changes
1.68M-1.97M1.40M-1.05M-0.91M-0.93M1.83M-1.88M-0.33M-2.12M0.82M0.09M-0.46M-0.78M1.74M-0.28M-0.66M2.79M0.46M-2.88M
Cash from OperationsCash from Ops.
-14.21M-19.05M-20.23M-18.47M-19.31M-19.09M-26.51M-47.90M-68.80M-27.75M-33.60M-63.90M-34.03M-33.00M-12.37M-29.90M-27.83M-15.52M-19.60M-20.80M
Investing Activities
Capital ExpendituresCapex
0.02M0.01M0.02M0.04M0.01M0.03M0.01M0.01M0.01M0.04M0.06M0.13M0.09M0.04M
Change in Property, Plant and EquipmentChange in PP&E
-0.02M-0.01M-0.02M-0.04M-0.01M-0.03M-0.01M-0.01M-0.01M-0.04M-0.06M-0.13M-0.09M-0.04M
Change in IntangiblesChange Intangibless
Acquisitions
Net of Acquisitions & DivestmentsNet Acquisitions
Purchase of InvestmentsInvestments Purchased
4.88M6.15M5.80M10.26M3.00M21.09M22.78M11.89M5.07M44.53M1.90M
Sale and Maturity of InvestmentsInvestments Sold
1.00M1.00M5.00M2.00M5.25M14.20M11.75M28.18M15.87M18.75M19.25M4.00M
Cash from Investing ActivitiesCash from Investing
-0.02M-0.01M-0.02M-0.04M-0.01M-0.03M-0.01M-4.88M-5.16M-4.83M-5.32M96.86M-15.93M-8.62M-3.14M23.11M-28.67M16.85M19.25M-1.00M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
22.50M
Long-Term Debt RepaymentsLT Debt Repayment
0.80M1.30M0.76M
Non-Current Debt
-0.80M-1.30M21.74M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.80M-1.30M21.74M
Change in Capital Stock
Common Stock IssuedStock Issued
-2.44M24.57M5.88M-0.02M54.84M62.15M-0.44M69.34M-0.28M0.10M0.16M0.14M5.63M86.91M146.09M0.00M0.08M
Shares Repurchased
0.44M
Net Shares Issued and RepurchasedNet Shares Issued
-2.44M24.57M5.88M-0.02M54.84M62.15M-0.89M69.34M-0.28M0.10M0.16M0.14M5.63M86.91M146.09M0.00M0.08M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
-2.44M24.57M5.88M-0.02M54.84M62.15M-0.89M69.34M-0.28M0.10M0.16M0.14M5.63M86.91M146.09M0.00M0.08M
Other financing activitiesOther financing
-0.01M
Cash from Financing ActivitiesCash from Financing
-4.44M24.57M4.96M-0.35M51.98M60.64M-2.12M69.34M21.21M0.10M20.16M0.14M5.63M86.91M146.09M0.00M0.08M
Additional items
Exchange Rate EffectFX Effect
-0.10M-0.12M-0.07M-0.20M-0.20M0.36M0.05M-0.01M-0.07M0.13M-0.06M-0.02M0.17M-0.24M0.07M0.14M0.00M0.00M-0.02M-0.01M
Change in Cash
-18.77M5.39M-15.36M-19.06M32.47M41.88M-28.60M43.02M-4.85M-32.36M-38.98M86.73M-49.80M-41.73M-15.43M-1.02M30.41M147.42M-0.37M-21.72M
Ending Cash Balance
77.72M83.11M67.74M48.68M81.15M123.03M94.43M137.46M132.60M100.25M61.27M148.00M98.20M56.48M41.04M40.02M70.44M217.85M217.49M195.77M
Free Cash FlowFCF
-14.23M-19.07M-20.25M-18.51M-19.32M-19.13M-26.52M-47.91M-68.81M-27.78M-33.66M-64.03M-34.12M-33.04M-12.37M-29.90M-27.83M-15.52M-19.60M-20.80M
Net Cash FlowNCF
-18.67M5.50M-15.30M-18.86M32.66M41.52M-28.65M16.55M-52.75M-32.48M-38.92M53.12M-49.96M-41.48M-15.51M-1.16M30.41M147.42M-0.35M-21.73M
Interest Paid

X4 Pharmaceuticals Cash Flow Statement API

Pull X4 Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=XFOR&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY